Valmark Advisers Inc. Invests $233,000 in Cencora, Inc. (NYSE:COR)

Valmark Advisers Inc. acquired a new position in shares of Cencora, Inc. (NYSE:COR) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,036 shares of the company’s stock, valued at approximately $233,000.

Several other large investors have also modified their holdings of the stock. Copperleaf Capital LLC lifted its holdings in shares of Cencora by 11.2% during the 4th quarter. Copperleaf Capital LLC now owns 4,662 shares of the company’s stock worth $1,047,000 after acquiring an additional 469 shares during the period. Allworth Financial LP lifted its holdings in shares of Cencora by 43.7% during the 4th quarter. Allworth Financial LP now owns 2,403 shares of the company’s stock worth $593,000 after acquiring an additional 731 shares during the period. Principal Securities Inc. lifted its holdings in shares of Cencora by 11.9% during the 4th quarter. Principal Securities Inc. now owns 20,821 shares of the company’s stock worth $4,678,000 after acquiring an additional 2,209 shares during the period. Everhart Financial Group Inc. lifted its holdings in shares of Cencora by 2.0% during the 4th quarter. Everhart Financial Group Inc. now owns 3,076 shares of the company’s stock worth $691,000 after acquiring an additional 61 shares during the period. Finally, Hickory Asset Management Inc. purchased a new position in shares of Cencora during the 4th quarter worth about $572,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

COR has been the subject of a number of research analyst reports. Barclays increased their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. increased their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Robert W. Baird increased their target price on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. UBS Group increased their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, Wells Fargo & Company increased their target price on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Stock Down 0.5 %

Shares of NYSE:COR opened at $241.37 on Wednesday. The company has a quick ratio of 0.53, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $262.26. The company has a 50 day moving average of $238.75 and a two-hundred day moving average of $237.41. The company has a market capitalization of $46.65 billion, a price-to-earnings ratio of 34.33, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts forecast that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend is Friday, February 14th. Cencora’s dividend payout ratio (DPR) is currently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.